Review

pep005 (pkc activator) (Cayman Chemical)

Cayman Chemical is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cayman Chemical pep005 (pkc activator)

Effect of drug treatments on viral persistence in the in vitro infection model (A) Assay overview. Schematic representation of the assay protocol involving the HIV-1 NL4-3 -infected cell culture model (Jurkat/NL cells). (B) Changes in supernatant p24 levels without drugs, with 5 nM <t>PEP005</t> or 50 nM EFdA, or with a combination of 50 nM EFdA and 5 nM PEP005 (n = 11, 9, 11, and 11, respectively). Drug treatment was terminated on week 9, but analysis continued for an additional 8 weeks. (C) Log rank test comparison of the percentage of non-recurrence in the EFdA single treatment and the combination treatment. (D) Changes in supernatant p24 levels in a representative experiment (experiment 1) from experiments shown in <xref ref-type=

pep005 (pkc activator) - by Bioz Stars, 2026-08

90/100 stars

Images

1) Product Images from "A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro"

Article Title: A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

Journal: Cell Reports Methods

doi: 10.1016/j.crmeth.2021.100122

Figure 3 B. (E and F) Assessment of the viral rebound in Jurkat/NL cells after drug discontinuation. Cells treated with drugs or untreated cells were stimulated with TNF-α (10 ng/mL) in week 17, and supernatant p24 (E) and intracellular p24 levels (F) were analyzed on day 6 after stimulation. Asterisk (∗) denotes below detection limit. " title="... supernatant p24 levels without drugs, with 5 nM PEP005 or 50 nM EFdA, or with a combination ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: Effect of drug treatments on viral persistence in the in vitro infection model (A) Assay overview. Schematic representation of the assay protocol involving the HIV-1 NL4-3 -infected cell culture model (Jurkat/NL cells). (B) Changes in supernatant p24 levels without drugs, with 5 nM PEP005 or 50 nM EFdA, or with a combination of 50 nM EFdA and 5 nM PEP005 (n = 11, 9, 11, and 11, respectively). Drug treatment was terminated on week 9, but analysis continued for an additional 8 weeks. (C) Log rank test comparison of the percentage of non-recurrence in the EFdA single treatment and the combination treatment. (D) Changes in supernatant p24 levels in a representative experiment (experiment 1) from experiments shown in Figure 3 B. (E and F) Assessment of the viral rebound in Jurkat/NL cells after drug discontinuation. Cells treated with drugs or untreated cells were stimulated with TNF-α (10 ng/mL) in week 17, and supernatant p24 (E) and intracellular p24 levels (F) were analyzed on day 6 after stimulation. Asterisk (∗) denotes below detection limit.

Techniques Used: In Vitro, Infection, Cell Culture, Comparison

Effect of various combinations of antiretroviral drugs and LRAs on viral persistence (A–C) Changes in HIV-1 production under treatment with 5 nM PEP005, 50 nM EFdA, and/or 500 nM DRV (protease inhibitor) (A); 5 nM PEP005 and/or 50 nM DTG (integrase inhibitor) (B); 100 nM EFdA, 500 nM SAHA (HDAC inhibitor), and/or 500 nM prostratin (PKC activator) (C). (D) EFdA at different concentrations (50 nM, 200 nM, or 1 μM) was examined. A higher concentration of EFdA (200 nM and 1 μM) slightly delayed the recurrence of supernatant viruses post treatment interruption. (E–H) Effect of different drug treatment protocols in the WIPE assay. (E) Changes in supernatant p24 levels with 50 nM EFdA for 9 weeks and then FFdA + PEP005 (5 nM) for an additional 9 weeks (n = 6). (F) Analysis of HIV-1 mRNA transcripts after TNF-α stimulation in cells without viral rebound on week 26 (three samples). (G) Changes in supernatant p24 levels with EFdA + PEP005 followed by the EFdA treatment for 9 weeks. (H) Analysis of HIV-1 mRNA transcripts after TNF-α stimulation in cells without viral rebound on week 26 (four samples). Asterisk (∗) represents below detection limit.

Figure Legend Snippet: Effect of various combinations of antiretroviral drugs and LRAs on viral persistence (A–C) Changes in HIV-1 production under treatment with 5 nM PEP005, 50 nM EFdA, and/or 500 nM DRV (protease inhibitor) (A); 5 nM PEP005 and/or 50 nM DTG (integrase inhibitor) (B); 100 nM EFdA, 500 nM SAHA (HDAC inhibitor), and/or 500 nM prostratin (PKC activator) (C). (D) EFdA at different concentrations (50 nM, 200 nM, or 1 μM) was examined. A higher concentration of EFdA (200 nM and 1 μM) slightly delayed the recurrence of supernatant viruses post treatment interruption. (E–H) Effect of different drug treatment protocols in the WIPE assay. (E) Changes in supernatant p24 levels with 50 nM EFdA for 9 weeks and then FFdA + PEP005 (5 nM) for an additional 9 weeks (n = 6). (F) Analysis of HIV-1 mRNA transcripts after TNF-α stimulation in cells without viral rebound on week 26 (three samples). (G) Changes in supernatant p24 levels with EFdA + PEP005 followed by the EFdA treatment for 9 weeks. (H) Analysis of HIV-1 mRNA transcripts after TNF-α stimulation in cells without viral rebound on week 26 (four samples). Asterisk (∗) represents below detection limit.

Techniques Used: Protease Inhibitor, Concentration Assay

HIV-1 infection dynamics with antiviral drugs in the WIPE assay (A) Fitting of the mathematical model to the experimental data in the WIPE assay without and with antiviral drug(s): numbers of uninfected and latently infected cells (cells/mL), virus-producing cells (cells/mL), supernatant p24 (pg/mL), and normalized proviral DNA. The shadowed regions correspond to 95% posterior predictive intervals, the solid lines gave the best-fit solution (mean) for the mathematical model, and the colored dots show the experimental datasets. All data were fitted simultaneously. (B) The distribution for the time until reactivation without and with PEP005 treatment calculated from all accepted MCMC parameter estimates is shown in green and blue, respectively. These lengths were significantly shorter with PEP005 treatment than without treatment, as assessed by the repeated bootstrap t test.

Figure Legend Snippet: HIV-1 infection dynamics with antiviral drugs in the WIPE assay (A) Fitting of the mathematical model to the experimental data in the WIPE assay without and with antiviral drug(s): numbers of uninfected and latently infected cells (cells/mL), virus-producing cells (cells/mL), supernatant p24 (pg/mL), and normalized proviral DNA. The shadowed regions correspond to 95% posterior predictive intervals, the solid lines gave the best-fit solution (mean) for the mathematical model, and the colored dots show the experimental datasets. All data were fitted simultaneously. (B) The distribution for the time until reactivation without and with PEP005 treatment calculated from all accepted MCMC parameter estimates is shown in green and blue, respectively. These lengths were significantly shorter with PEP005 treatment than without treatment, as assessed by the repeated bootstrap t test.

Techniques Used: Infection, Virus

Mechanisms for the elimination of HIV-1 producible cells in vitro (A) Quantification of intracellular copies of HIV-1 DNA at each time point in experiment 6 ( <xref ref-type=

Figure S2 A). (B) Schematic representation of the individual provirus structures from two different treatment groups and at two time points in experiment 6. Each horizontal bar represents an individual HIV-1 genome, as determined by amplification of near full-length HIV-1 DNA from a single HIV-1 genome and DNA sequencing. The gray bars denote full-length types, and the red bars indicate defective proviruses. (C) Pie charts reflecting the proportion of defective and intact proviruses in experiment 6. (D) Pie charts reflecting the proportion of defective and intact proviruses in PBMCs from three HIV-1-infected individuals. (E) Quantification of intracellular copies of HIV-1 DNA at each time point in experiment 1 ( Figure 3 D). (F) Schematic representation of the individual provirus structures in experiment 1 for the EFdA/PEP005 culture group 17 weeks after drug treatment initiation. (G) Pie chart showing the relative abundance of each HIV-1-infected clone. Chromosomal number and position of each clone are shown in the right panel. (H) Schematic figure of the provirus structure and IS in the expanded clone. A 467-basepair deletion in the 5′ end of 5′ LTR was observed. TSS, transcription start site. Asterisk (∗) represents below detection limit. " title="... individual provirus structures in experiment 1 for the EFdA/PEP005 culture group 17 weeks after drug treatment initiation. ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: Mechanisms for the elimination of HIV-1 producible cells in vitro (A) Quantification of intracellular copies of HIV-1 DNA at each time point in experiment 6 ( Figure S2 A). (B) Schematic representation of the individual provirus structures from two different treatment groups and at two time points in experiment 6. Each horizontal bar represents an individual HIV-1 genome, as determined by amplification of near full-length HIV-1 DNA from a single HIV-1 genome and DNA sequencing. The gray bars denote full-length types, and the red bars indicate defective proviruses. (C) Pie charts reflecting the proportion of defective and intact proviruses in experiment 6. (D) Pie charts reflecting the proportion of defective and intact proviruses in PBMCs from three HIV-1-infected individuals. (E) Quantification of intracellular copies of HIV-1 DNA at each time point in experiment 1 ( Figure 3 D). (F) Schematic representation of the individual provirus structures in experiment 1 for the EFdA/PEP005 culture group 17 weeks after drug treatment initiation. (G) Pie chart showing the relative abundance of each HIV-1-infected clone. Chromosomal number and position of each clone are shown in the right panel. (H) Schematic figure of the provirus structure and IS in the expanded clone. A 467-basepair deletion in the 5′ end of 5′ LTR was observed. TSS, transcription start site. Asterisk (∗) represents below detection limit.

Techniques Used: In Vitro, Amplification, DNA Sequencing, Infection

Figure Legend Snippet:

Techniques Used: Virus, Infection, Recombinant, Flow Cytometry, Binding Assay, SYBR Green Assay, Purification, Sensitive Assay, Library Quantification, CCK-8 Assay, Software

Image Search Results

The upper part of this figure demonstrates the charts of flow cytometry detecting apoptosis of cultured HAECs treated with H/R, baicalin (10, 20, and 40 μmol/l), and PEP005. Columns on the left side of the lower panel indicate the apoptotic rate of cultured HAECs. Columns on the right side of the lower panel indicate the cell viabilities of cultured HAECs. [ a differences were significant when compared with Control (p<0.05); b differences were significant when compared with H/R (p<0.05); c differences were significant when compared with H/R+Bac-10μmol/l (p<0.05); d differences were significant when compared with H/R+Bac-20 μmol/l (p<0.05); e differences were significant when compared with H/R+Bac-40 μmol/l (p<0.05)].

Journal: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

Article Title: Baicalin Suppresses Hypoxia-Reoxygenation-Induced Arterial Endothelial Cell Apoptosis via Suppressing PKCδ/p53 Signaling

doi: 10.12659/MSM.907989

Figure Lengend Snippet: The upper part of this figure demonstrates the charts of flow cytometry detecting apoptosis of cultured HAECs treated with H/R, baicalin (10, 20, and 40 μmol/l), and PEP005. Columns on the left side of the lower panel indicate the apoptotic rate of cultured HAECs. Columns on the right side of the lower panel indicate the cell viabilities of cultured HAECs. [ a differences were significant when compared with Control (p<0.05); b differences were significant when compared with H/R (p<0.05); c differences were significant when compared with H/R+Bac-10μmol/l (p<0.05); d differences were significant when compared with H/R+Bac-20 μmol/l (p<0.05); e differences were significant when compared with H/R+Bac-40 μmol/l (p<0.05)].

Article Snippet: Several cells were also treated with PKC activator PEP005 (Sigma-Aldrich) at a final concentration of 0.1 μmol/l for 12 h. Several cells were also infected with specific small interfering RNA (siRNA) against PKCδ.

Techniques: Flow Cytometry, Cell Culture

The upper part of this figure shows the immunoblots of p-PKCδ, PKCδ, p-p53, p53, active caspase3, bax, and GAPDH in cultured HAECs treated with H/R, baicalin (10, 20, and 40 μmol/l) and PEP005. Columns on the left part of lower panel indicate the relative phosphorylation levels of PKCδ (white) and p53 (blue) in HAECs, respectively. Columns on the right part of lower panel indicate the relative expression levels of active caspase3 (white) and bax (blue) in HAECs, respectively. [ a differences were significant when compared with Control (p<0.05); b differences were significant when compared with H/R (p<0.05); c differences were significant when compared with H/R+Bac-10μmol/l (p<0.05); d differences were significant when compared with H/R+Bac-20 μmol/l (p<0.05); e differences were significant when compared with H/R+Bac-40 μmol/l (p<0.05)].

Journal: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

Article Title: Baicalin Suppresses Hypoxia-Reoxygenation-Induced Arterial Endothelial Cell Apoptosis via Suppressing PKCδ/p53 Signaling

doi: 10.12659/MSM.907989

Figure Lengend Snippet: The upper part of this figure shows the immunoblots of p-PKCδ, PKCδ, p-p53, p53, active caspase3, bax, and GAPDH in cultured HAECs treated with H/R, baicalin (10, 20, and 40 μmol/l) and PEP005. Columns on the left part of lower panel indicate the relative phosphorylation levels of PKCδ (white) and p53 (blue) in HAECs, respectively. Columns on the right part of lower panel indicate the relative expression levels of active caspase3 (white) and bax (blue) in HAECs, respectively. [ a differences were significant when compared with Control (p<0.05); b differences were significant when compared with H/R (p<0.05); c differences were significant when compared with H/R+Bac-10μmol/l (p<0.05); d differences were significant when compared with H/R+Bac-20 μmol/l (p<0.05); e differences were significant when compared with H/R+Bac-40 μmol/l (p<0.05)].

Techniques: Western Blot, Cell Culture, Expressing

Journal: Cell Reports Methods

Article Title: A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

doi: 10.1016/j.crmeth.2021.100122

Figure Lengend Snippet: Effect of drug treatments on viral persistence in the in vitro infection model (A) Assay overview. Schematic representation of the assay protocol involving the HIV-1 NL4-3 -infected cell culture model (Jurkat/NL cells). (B) Changes in supernatant p24 levels without drugs, with 5 nM PEP005 or 50 nM EFdA, or with a combination of 50 nM EFdA and 5 nM PEP005 (n = 11, 9, 11, and 11, respectively). Drug treatment was terminated on week 9, but analysis continued for an additional 8 weeks. (C) Log rank test comparison of the percentage of non-recurrence in the EFdA single treatment and the combination treatment. (D) Changes in supernatant p24 levels in a representative experiment (experiment 1) from experiments shown in Figure 3 B. (E and F) Assessment of the viral rebound in Jurkat/NL cells after drug discontinuation. Cells treated with drugs or untreated cells were stimulated with TNF-α (10 ng/mL) in week 17, and supernatant p24 (E) and intracellular p24 levels (F) were analyzed on day 6 after stimulation. Asterisk (∗) denotes below detection limit.

Article Snippet: PEP005 (PKC activator) was purchased from Cayman Chemical (Ann Arbor, MI); SAHA (vorinostat; HDAC inhibitor) from Santa Cruz Biotechnology (Dallas, TX); JQ-1 (BRD4 inhibitor) from BioVision (Milpitas, CA); GSK525762A (BRD4 inhibitor) from ChemScene (Monmouth Junction, NJ); Ro5-3335 from Merck (Darmstadt, Germany).

Techniques: In Vitro, Infection, Cell Culture, Comparison

Journal: Cell Reports Methods

Article Title: A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

doi: 10.1016/j.crmeth.2021.100122

Figure Lengend Snippet: Effect of various combinations of antiretroviral drugs and LRAs on viral persistence (A–C) Changes in HIV-1 production under treatment with 5 nM PEP005, 50 nM EFdA, and/or 500 nM DRV (protease inhibitor) (A); 5 nM PEP005 and/or 50 nM DTG (integrase inhibitor) (B); 100 nM EFdA, 500 nM SAHA (HDAC inhibitor), and/or 500 nM prostratin (PKC activator) (C). (D) EFdA at different concentrations (50 nM, 200 nM, or 1 μM) was examined. A higher concentration of EFdA (200 nM and 1 μM) slightly delayed the recurrence of supernatant viruses post treatment interruption. (E–H) Effect of different drug treatment protocols in the WIPE assay. (E) Changes in supernatant p24 levels with 50 nM EFdA for 9 weeks and then FFdA + PEP005 (5 nM) for an additional 9 weeks (n = 6). (F) Analysis of HIV-1 mRNA transcripts after TNF-α stimulation in cells without viral rebound on week 26 (three samples). (G) Changes in supernatant p24 levels with EFdA + PEP005 followed by the EFdA treatment for 9 weeks. (H) Analysis of HIV-1 mRNA transcripts after TNF-α stimulation in cells without viral rebound on week 26 (four samples). Asterisk (∗) represents below detection limit.

Techniques: Protease Inhibitor, Concentration Assay

Journal: Cell Reports Methods

Article Title: A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

doi: 10.1016/j.crmeth.2021.100122

Figure Lengend Snippet: HIV-1 infection dynamics with antiviral drugs in the WIPE assay (A) Fitting of the mathematical model to the experimental data in the WIPE assay without and with antiviral drug(s): numbers of uninfected and latently infected cells (cells/mL), virus-producing cells (cells/mL), supernatant p24 (pg/mL), and normalized proviral DNA. The shadowed regions correspond to 95% posterior predictive intervals, the solid lines gave the best-fit solution (mean) for the mathematical model, and the colored dots show the experimental datasets. All data were fitted simultaneously. (B) The distribution for the time until reactivation without and with PEP005 treatment calculated from all accepted MCMC parameter estimates is shown in green and blue, respectively. These lengths were significantly shorter with PEP005 treatment than without treatment, as assessed by the repeated bootstrap t test.

Techniques: Infection, Virus

Journal: Cell Reports Methods

Article Title: A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

doi: 10.1016/j.crmeth.2021.100122

Figure Lengend Snippet: Mechanisms for the elimination of HIV-1 producible cells in vitro (A) Quantification of intracellular copies of HIV-1 DNA at each time point in experiment 6 ( Figure S2 A). (B) Schematic representation of the individual provirus structures from two different treatment groups and at two time points in experiment 6. Each horizontal bar represents an individual HIV-1 genome, as determined by amplification of near full-length HIV-1 DNA from a single HIV-1 genome and DNA sequencing. The gray bars denote full-length types, and the red bars indicate defective proviruses. (C) Pie charts reflecting the proportion of defective and intact proviruses in experiment 6. (D) Pie charts reflecting the proportion of defective and intact proviruses in PBMCs from three HIV-1-infected individuals. (E) Quantification of intracellular copies of HIV-1 DNA at each time point in experiment 1 ( Figure 3 D). (F) Schematic representation of the individual provirus structures in experiment 1 for the EFdA/PEP005 culture group 17 weeks after drug treatment initiation. (G) Pie chart showing the relative abundance of each HIV-1-infected clone. Chromosomal number and position of each clone are shown in the right panel. (H) Schematic figure of the provirus structure and IS in the expanded clone. A 467-basepair deletion in the 5′ end of 5′ LTR was observed. TSS, transcription start site. Asterisk (∗) represents below detection limit.

Techniques: In Vitro, Amplification, DNA Sequencing, Infection

Journal: Cell Reports Methods

Article Title: A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

doi: 10.1016/j.crmeth.2021.100122

Figure Lengend Snippet:

Techniques: Virus, Infection, Recombinant, Flow Cytometry, Binding Assay, SYBR Green Assay, Purification, Sensitive Assay, Library Quantification, CCK-8 Assay, Software

Review

Structured Review

Images

1) Product Images from "A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro"

Similar Products

Image Search Results